Publicaitons Below are Selected Peer-reviewed Publications (in chronological order): Selected from over 450 publications (A complete list of Dr. Eric Hollander’s published works can be found: https://www.ncbi.nlm.nih.gov/pubmed?term=Hollander+Eric&cmd=DetailsSearch) Pallanti S, Zohar J, Kasper S, Möller HJ, Hollander E. Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach. J Psychiatr Res. 2023 Dec 2;170:65-72. Vismara M, Benatti B, Fineberg NA, Hollander E, Van Ameringen M, Menchon JM, Zohar J, Dell'Osso B. Lessons from a multicenter, international, large sample size analysis of patients with obsessive-compulsive disorders: an overview of the ICOCS Snapshot studies. CNS Spectr. 2023 Sep 11:1-9. Tobe R, Zhu Y, Gleissl T, Rossomanno S, Veenstra-VanderWeele J, Smith J, Hollander E. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder. Neuropsychopharmacology. 2023 Jul;48(8):1201-1216. Taoulost S, Rasgon N, Ferretti CJ, Hollander E. The role of ketogenic therapy in developmental disorders. J Psychiatr Res. 2023 May;161:307-309. Piccoli E, Hollander E. Editor's Commentary: Problematic Use of the internet in Autism Spectrum Disorder: A canary in the coal mine? J Psychiatr Res. 2022 Nov;155:260-262. Hollander E, Jacob S, Jou R, McNamara N, Sikich L, Tobe R, Smith J, Sanders K, Squassante L, Murtagh L, Gleissl T, Wandel C, Veenstra-VanderWeele J. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Aug 1;79(8):760-769. Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Focus (Am Psychiatr Publ). 2022 Jan;20(1):152-159. Jacob S, Anagnostou E, Hollander E, Jou R, McNamara N, Sikich L, Tobe R, Murphy D, McCracken J, Ashford E, Chatham C, Clinch S, Smith J, Sanders K, Murtagh L, Noeldeke J, Veenstra-VanderWeele J. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. Mol Autism. 2022 Jun 11;13(1):25. Fineberg NA, Hollander E, Grant JE, Chamberlain SR, Drummond LM, Pellegrini L, Laws KR, Wellsted D, Reid J, Nezgovorova V, Baldwin DS. Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., JAMA Psychiatry. 2022;79(3):193-200 (1). Compr Psychiatry. 2022 Jul;116:152323. Simonoff E, Mowlem F, Pearson O, Anagnostou E, Donnelly C, Hollander E, King BH, McCracken JT, Scahill L, Sikich L, Pickles A. Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors. J Child Adolesc Psychopharmacol. 2022 May;32(4):233-241. Benatti B, Girone N, Celebre L, Vismara M, Hollander E, Fineberg NA, Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M, Lochner C, Karamustafalioglu O, Hranov L, Figee M, Drummond LM, Grant JE, Denys D, Fontenelle LF, Menchon JM, Zohar J, Rodriguez CI, Dell'Osso B. The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. Compr Psychiatry. 2022 Jul;116:152315. Taylor BP, Liu J, Mowrey W, Eule E, Bolognani F, Hollander E. The Montefiore-Einstein Rigidity Scale-Revised (MERS-R): Development, administration, reliability, and validity in child and adult Autism Spectrum Disorder (ASD). J Psychiatr Res. 2022 Mar;147:142-147 Nezgovorova V, Ferretti CJ, Pallanti S, Hollander E. Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder. J Psychiatr Res. 2022 May;149:367-373. Uzunova G, Pallanti S, Hollander E. Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. Int J Psychiatry Clin Pract. 2021 Jun;25(2):115-131. Hollander E, Levine KG, Ferretti CJ, Freeman K, Doernberg E, Desilva N, Taylor BP. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial. J Psychiatr Res. 2021 May;137:643-651. Fineberg NA, Hollander E, Pallanti S, Walitza S, Grünblatt E, Dell'Osso BM, Albert U, Geller DA, Brakoulias V, Janardhan Reddy YC, Arumugham SS, Shavitt RG, Drummond L, Grancini B, De Carlo V, Cinosi E, Chamberlain SR, Ioannidis K, Rodriguez CI, Garg K, Castle D, Van Ameringen M, Stein DJ, Carmi L, Zohar J, Menchon JM. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Int Clin Psychopharmacol. 2020 Jul;35(4):173-193. Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Noeldeke J, Boak L, Khwaja O, Sadikhov S, Fontoura P, Umbricht D. Correction to: Exploring Social Biomarkers in High‑Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross‑Sectional Analysis. J Autism Dev Disord. 2020 Dec;50(12):4431-4432. Hollander E, Uzunova G, Taylor BP, Noone R, Racine E, Doernberg E, Freeman K, Ferretti CJ. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World J Biol Psychiatry. 2020 Apr;21(4):291-299. Burchi E, Hollander E, Pallanti S. From Treatment Response to Recovery: A Realistic Goal in OCD. Int J Neuropsychopharmacol. 2018 Nov 1;21(11):1007-1013. Fineberg, N. A., Demetrovics, Z., Stein, D. J., Ioannidis, K., Potenza, M. N., Grünblatt, E., ...Hollander, E., … & Grant, J. E. (2018). Manifesto for a European research network into Problematic Usage of the Internet. European Neuropsychopharmacology, 28(11), 1232-1246. Del Valle Rubido, M., McCracken, J. T., Hollander, E., Shic, F., Noeldeke, J., Boak, L., ... & Umbricht, D. (2018). In Search of Biomarkers for Autism Spectrum Disorder. Autism Research, 11(11), 1567-1579. Hollander, E., Uzunova, G., Taylor, B. P., Noone, R., Racine, E., Doernberg, E.,... & Ferretti, C. J. (2018). Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. The World Journal of Biological Psychiatry, 1-9. Burchi, E., Hollander, E., & Pallanti, S. (2018). From treatment response to recovery: a realistic goal in OCD. International Journal of Neuropsychopharmacology, 21(11), 1007-1013. Development of Oxytocin and Vasopressin 1a antagonists for Social Communication and Repetitive Behaviors in autism spectrum disorder and related conditions: Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology 28(1):193-8, 2003. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 15;61(4):498-503, 2007. Epub 2006 Aug 10 Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism, 2012. 3(1): p. 16. Kabasakalian A., Ferretti C.J., Hollander E. (2017) Oxytocin and Prader-Willi Syndrome. In: Hurlemann R., Grinevich V. (eds) Behavioral Pharmacology of Neuropeptides: Oxytocin. Current Topics in Behavioral Neurosciences, vol 35. Springer, Cham Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, et al. Oxytocin selectively improves empathic accuracy. Psychol Sci. 21(1):1426-8, 2010. Umbricht, D., del Valle Rubido, M., Hollander, E., McCracken, J. T., Shic, F., Scahill, L., ... & Grundschober, C. (2017). A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology, 42(9), 1914. Del Valle Rubido, M., McCracken, J. T., Hollander, E., Shic, F., Noeldeke, J., Boak, L., ... & Umbricht, D. (2018). In Search of Biomarkers for Autism Spectrum Disorder. Autism Research, 11(11), 1567-1579 Development of Novel Treatments for the Repetitive Behavior Domain in ASD: Hollander, E., Uzunova, G., Taylor, B. P., Noone, R., Racine, E., Doernberg, E.,... & Ferretti, C. J. (2018). Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. The World Journal of Biological Psychiatry, 1-9. King BH…Hollander E et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013 Nov;167(11):1045-52. Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C. A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and global Severity in Adult Autism Spectrum Disorders. Am J Psychiatry. 2011 Dec 2
